Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
KisqaliⓇ - CDK4 inhibitor
Conclusions
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
NCT03701334 NATALEE (CLEE011012301C)
Indication
Phase
Patients
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Adjuvant treatment of hormone receptor (HR)-positive, HER2-negative, early
breast cancer (EBC)
Phase 3
5101
Invasive Disease-Free Survival for using STEEP criteria (Standardized
Definitions for Efficacy End Points in adjuvant breast cancer trials)
Ribociclib endocrine therapy
Endocrine therapy
Pre and postmenopausal women and men with HR-positive, HER2-negative
EBC, after adequate surgical resection, who are eligible for adjuvant endocrine
therapy
2023 (actual)
Readout
Milestone(s)
Publication
TBD
71 Investor Relations | Q2 2023 Results
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation